In this episode of Derms and Conditions, Dr James Q. Del Rosso welcomes back his
longtime friend and pediatric dermatology expert, Dr Lisa Swanson. Together, they
explore the rapidly evolving treatment landscape for pediatric atopic dermatitis, with a
focus on newly approved non-steroidal topical therapies.
Dr Swanson shares her insights on tapinarof 1% cream, now FDA-approved for patients
as young as two years old, and topical roflumilast 0.15% cream, approved down to age
six. The duo discusses how aryl hydrocarbon receptor (AhR) agonism makes tapinarof
effective in both atopic dermatitis and psoriasis, likening its action to a “SNOO” that
adjusts to soothe inflammation.
They also dive into data from the ADORING 1 and ADORING 2 phase 3 trials,
highlighting tapinarof’s rapid reduction in itch and its positive impact on sleep—critical
outcomes for both children and their parents. Dr Swanson offers real-world anecdotes
about the sleep-depriving toll of pediatric eczema and how effective therapies can
restore rest for the entire family.
The conversation touches on skin of color considerations, including how atopic
dermatitis may present differently and why diverse representation in clinical trials is
essential. Dr Swanson underscores the importance of tactile assessments and shares
practical pearls for evaluating eczema severity across skin types.
Finally, they explore safety and tolerability, emphasizing tapinarof’s low risk of systemic
absorption, even in young children prone to thumb-sucking or hand-to-mouth behavior.
Tune in for clinical pearls, new treatment insights, and a few laughs between two
dermatology BFFs.